Clinical Trials Logo

Juvenile Dermatomyositis (JDM) clinical trials

View clinical trials related to Juvenile Dermatomyositis (JDM).

Filter by:
  • None
  • Page 1

NCT ID: NCT05000216 Completed - Clinical trials for Rheumatoid Arthritis (RA)

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Start date: August 13, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result >200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 vaccine. The study will focus on 5 autoimmune diseases in adults: - Systemic Lupus Erythematosus (SLE) - Rheumatoid Arthritis (RA) - Multiple Sclerosis (MS) - Systemic Sclerosis (SSc), and - Pemphigus. This study will focus on 4 autoimmune diseases in pediatric participants: - Systemic Lupus Erythematosus (SLE) - Juvenile Idiopathic Arthritis (JIA) - Pediatric-Onset Multiple Sclerosis (POMS) - Juvenile Dermatomyositis (JDM)

NCT ID: NCT01724580 No longer available - Clinical trials for Aicardi-Goutières Syndrome (AGS)

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

Start date: n/a
Phase:
Study type: Expanded Access

The Requesting Physician/Investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.